LeMaitre Vascular, Inc. $LMAT Shares Purchased by ProShare Advisors LLC

ProShare Advisors LLC raised its stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 9.5% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 74,110 shares of the medical instruments supplier’s stock after buying an additional 6,403 shares during the quarter. ProShare Advisors LLC’s holdings in LeMaitre Vascular were worth $6,010,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the stock. State of Alaska Department of Revenue grew its holdings in LeMaitre Vascular by 1.2% during the 4th quarter. State of Alaska Department of Revenue now owns 11,986 shares of the medical instruments supplier’s stock valued at $971,000 after buying an additional 147 shares during the last quarter. Johnson Investment Counsel Inc. grew its holdings in LeMaitre Vascular by 0.5% during the 3rd quarter. Johnson Investment Counsel Inc. now owns 29,792 shares of the medical instruments supplier’s stock valued at $2,607,000 after buying an additional 153 shares during the last quarter. Federated Hermes Inc. grew its holdings in LeMaitre Vascular by 0.4% during the 2nd quarter. Federated Hermes Inc. now owns 39,659 shares of the medical instruments supplier’s stock valued at $3,294,000 after buying an additional 155 shares during the last quarter. Jones Financial Companies Lllp grew its holdings in LeMaitre Vascular by 2.2% during the 3rd quarter. Jones Financial Companies Lllp now owns 7,486 shares of the medical instruments supplier’s stock valued at $630,000 after buying an additional 158 shares during the last quarter. Finally, Illinois Municipal Retirement Fund grew its holdings in LeMaitre Vascular by 1.6% during the 3rd quarter. Illinois Municipal Retirement Fund now owns 11,048 shares of the medical instruments supplier’s stock valued at $967,000 after buying an additional 171 shares during the last quarter. Institutional investors and hedge funds own 84.64% of the company’s stock.

LeMaitre Vascular Trading Down 1.8%

Shares of LMAT opened at $97.75 on Friday. The company has a current ratio of 14.32, a quick ratio of 12.20 and a debt-to-equity ratio of 0.42. The firm has a market capitalization of $2.23 billion, a P/E ratio of 36.07, a price-to-earnings-growth ratio of 2.76 and a beta of 0.60. The stock’s fifty day simple moving average is $108.54 and its 200 day simple moving average is $95.31. LeMaitre Vascular, Inc. has a twelve month low of $78.35 and a twelve month high of $118.01.

LeMaitre Vascular (NASDAQ:LMAT) last issued its earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.68 earnings per share for the quarter, topping the consensus estimate of $0.66 by $0.02. The business had revenue of $66.55 million for the quarter, compared to analyst estimates of $66.67 million. LeMaitre Vascular had a return on equity of 15.36% and a net margin of 24.35%.The business’s quarterly revenue was up 11.1% on a year-over-year basis. During the same period last year, the company posted $0.48 EPS. LeMaitre Vascular has set its FY 2026 guidance at 2.930-3.080 EPS and its Q2 2026 guidance at 0.790-0.840 EPS. On average, equities research analysts forecast that LeMaitre Vascular, Inc. will post 3 earnings per share for the current year.

LeMaitre Vascular Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, June 4th. Investors of record on Thursday, May 21st will be given a $0.25 dividend. This represents a $1.00 annualized dividend and a dividend yield of 1.0%. The ex-dividend date of this dividend is Thursday, May 21st. LeMaitre Vascular’s dividend payout ratio (DPR) is 36.90%.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on LMAT shares. Roth Mkm restated a “buy” rating and set a $117.00 price objective (up from $108.00) on shares of LeMaitre Vascular in a report on Thursday, February 26th. Weiss Ratings upgraded LeMaitre Vascular from a “buy (b-)” rating to a “buy (b)” rating in a report on Wednesday. Barrington Research raised their price objective on LeMaitre Vascular from $105.00 to $120.00 and gave the stock an “outperform” rating in a report on Wednesday, May 6th. Wall Street Zen upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. Finally, Zacks Research upgraded LeMaitre Vascular from a “hold” rating to a “strong-buy” rating in a report on Monday, April 13th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $112.60.

Insider Transactions at LeMaitre Vascular

In related news, insider Trent G. Kamke sold 2,928 shares of the stock in a transaction on Friday, May 8th. The stock was sold at an average price of $107.00, for a total value of $313,296.00. Following the transaction, the insider directly owned 3,749 shares of the company’s stock, valued at approximately $401,143. This trade represents a 43.85% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director David B. Roberts sold 8,464 shares of the stock in a transaction on Friday, February 27th. The stock was sold at an average price of $106.80, for a total value of $903,955.20. Following the completion of the transaction, the director directly owned 17,979 shares in the company, valued at $1,920,157.20. This trade represents a 32.01% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 269,891 shares of company stock valued at $28,969,086. Corporate insiders own 7.40% of the company’s stock.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.